EPO906 Therapy in Patients With Advanced Colorectal Cancer

Inclusion Criteria Patients must meet the following criteria to be eligible for the study: * Histologically or cytologically documented evidence of colorectal cancer with at least one measurable lesion (if previous radiation treatment, the target lesion must have demonstrated progression since the radiation) * The patient should have failed or progressed on no more than two prior chemotherapies for metastatic disease (the prior chemotherapy must have included a fluoropyrimidine and either Irinotecan or oxaliplatin, or any combination of these agents, with the last chemotherapy having contained Irinotecan or oxaliplatin) * Patients who have received only adjuvant therapy for their disease are eligible, as long as they have relapsed within six months of completing such therapy and that therapy contained 5-FU and Irinotecan or oxaliplatin administered in combination as part of an investigational protocol * Must have a life expectancy of greater than three (3) months. Exclusion Criteria The following patients are not eligible for the study: * Patients with symptomatic CNS metastases or leptomeningeal involvement * Patients with unresolved bowel obstruction * Patients with any peripheral neuropathy or unresolved diarrhea greater than Grade 1 * Patients with severe cardiac insufficiency * Patients who have undergone major surgery for any cause less than 4 weeks prior to study entry * Patients with radiation therapy or chemotherapy within the last four weeks * Patients taking Coumadin or other warfarin-containing agents with the exception of low dose Coumadin (1 mg or less) for the maintenance of in-dwelling lines or ports * History of another malignancy within 5 years prior to study entry except curatively treated non-melanoma skin cancer or cervical cancer in situ * Patients with active or suspected acute or chronic uncontrolled infection including abcesses or fistulae * HIV+ patients * Pregnant or lactating females